Basecamp Research raises more in one round than in its first seven years combined

Basecamp Research announced a $140M oversubscribed Series C on Sept 23, 2026, led by S32, to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics towards clinical development, starting with in vivo cell therapy, and expand pharmaceutical partnerships.

Sixteen participants are named in the round: S32 (lead), Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand, River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures, with additional investment from senior leaders across pharma, biotech and global industry.

Basecamp is applying EDEN, its biological foundation model, to in vivo cell therapy, reprogramming a patient's cells inside the body, by pairing EDEN's ability to design long and complex DNA sequences with large serine recombinases that precisely integrate them into the genome, aiming to make cell therapies more sophisticated, more customisable and simpler to administer.

The company says it has demonstrated strong preclinical results across multiple modalities and disease areas.

Today's cell therapies are limited both in the complexity of what they can deliver and by a manufacturing process that costs hundreds of thousands of dollars per patient.

The Trillion Gene Atlas, described by the company as the world's largest proprietary biological AI training dataset, was built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, and draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents.

"We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how," said Glen Gowers, co-founder and CEO of Basecamp Research.

Additional investment came from senior leaders including Andre Hoffmann, Vice-Chairman of Roche, who said: "Personalised, AI-designed therapeutics represent the next transformation of that journey."

To expand its pharmaceutical partnerships, Basecamp has appointed Richard Pearce, formerly of Biogen, as Chief Business Officer.

About $85M was raised before this round, covering the period from the 2019 founding to September 2026.

The Series C is roughly 1.6 times all capital raised before it.

The Series C is 62 percent of the company's lifetime capital raised.

NVIDIA's venture arm NVentures is a returning investor, and Anthropic's Anthology Fund, a partnership between Anthropic and US VC Menlo Ventures, is a new investor; tech.eu's headline describes the round as having participation from Anthropic.

Other new investors are Catalio, the NATO Innovation Fund, Rockefeller, European Tech Collective and the UK government's Sovereign AI Fund; returning investors include Firebrand, River Capital, King Philanthropies and Redalpine.

Neither announcement gives a valuation for the round, a named lead therapeutic candidate, a target indication or a regulatory filing date; the pipeline is identified by modality, in vivo cell therapy.

Six of the sixteen named participants are state-backed, philanthropic or corporate strategic investors rather than conventional venture funds: the NATO Innovation Fund, the UK government's Sovereign AI Fund, the Rockefeller Foundation, King Philanthropies, NVIDIA and Anthropic's Anthology Fund.

Split evenly across the sixteen named participants, the round averages under $9M each.

Taking hundreds of thousands of dollars per patient as $200,000 to $500,000, the $140M round equals between 280 and 700 patients of current-generation cell therapy manufacturing.